Keros Therapeutics, Inc. (KROS) vs MacroGenics, Inc. (MGNX)
- Keros Therapeutics, Inc. KROS 10.66 −3.96%
- MacroGenics, Inc. MGNX 3.25 −3.56%
Keros Therapeutics, Inc. and MacroGenics, Inc. are both Biotechnology companies. Keros Therapeutics, Inc. and MacroGenics, Inc. are of similar size ($220.1M and $214.7M). MacroGenics, Inc. grew revenue faster over the last twelve months: 21.9% against −84.6%. Keros Therapeutics, Inc. has the higher net margin (0.00% vs −7.97%) and the lower return on invested capital (−1,345.3% vs 0.00%). Across the 17 metrics below, Keros Therapeutics, Inc. leads on 12 and MacroGenics, Inc. on 5.
Valuation
Profitability
| Metric | KROS | MGNX | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 78.07% | 65.16% |
| Operating margin | 0.00% | (18.73%) | 0.00% |
| Net margin | 0.00% | (7.97%) | 0.00% |
| Free cash flow margin | 0.00% | (35.80%) | 0.00% |
| Return on equity | (17.16%) | (32.61%) | (56.36%) |
| Return on assets | (15.92%) | (4.94%) | (48.04%) |
| Return on invested capital | (1,345.30%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack